{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:17:34Z","timestamp":1788967054872,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmc.2022.116912","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:34:26Z","timestamp":1657283666000},"page":"116912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS\/STING immunity pathway combined with daunorubicin"],"prefix":"10.1016","volume":"70","author":[{"given":"Shanshan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihui","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingna","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.116912_b0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrm3376","article-title":"New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs","volume":"13","author":"Gibson","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2022.116912_b0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: parp1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2022.116912_b0015","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"10","key":"10.1016\/j.bmc.2022.116912_b0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2022.116912_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2022.116912_b0030","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/cancers12061503","article-title":"Identifying and overcoming mechanisms of PARP inhibitor resistance in homologous recombination repair-deficient and repair-proficient high grade serous ovarian cancer cells","volume":"12","author":"Gomez","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bmc.2022.116912_b0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2022.116912_b0040","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41589-020-0609-7","article-title":"Functional characterization of a PROTAC directed against BRAF mutant V600E","volume":"16","author":"Posternak","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2022.116912_b0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.bmc.2022.116912_b0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1039\/C8CC07813K","article-title":"Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmc.2022.116912_b0055","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41589-019-0379-2","article-title":"Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2022.116912_b0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2022.116912_b0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2017.07.008","article-title":"Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives","volume":"59","author":"Ventriglia","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2022.116912_b0070","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-Dependent antitumor immunity in Brca1-Deficient ovarian Cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.bmc.2022.116912_b0075","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.bmc.2022.116912_b0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","article-title":"Type I interferon response and innate immune sensing of cancer","volume":"34","author":"Fuertes","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bmc.2022.116912_b0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and Cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmc.2022.116912_b0090","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.116912_b0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"7577","key":"10.1016\/j.bmc.2022.116912_b0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.116912_b0105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2022.116912_b0110","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2022.116912_b0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bmc.2022.116912_b0120","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2022.116912_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.08.006","article-title":"The rise and rise of protein degradation: opportunities and challenges ahead","author":"Hughes","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2022.116912_b0130","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1093\/nar\/gku474","article-title":"PARP-2 and PARP-3 are selectively activated by 5\u2032 phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1","volume":"42","author":"Langelier","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2022.116912_b0135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1039\/c3np20126k","article-title":"From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes","volume":"30","author":"Kim","year":"2013","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.bmc.2022.116912_b0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ","volume":"37","author":"Brownell","year":"2010","journal-title":"Mol Cell"},{"issue":"40","key":"10.1016\/j.bmc.2022.116912_b0145","doi-asserted-by":"crossref","first-page":"28379","DOI":"10.1074\/jbc.274.40.28379","article-title":"Cleavage of Automodified Poly(ADP-ribose) Polymerase during Apoptosis","volume":"274","author":"Germain","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2022.116912_b0150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA Repair: Additional Functions of PARP-1 in Cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2022.116912_b0155","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bmc.2022.116912_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119527","article-title":"A comprehensive review on time-tested anticancer drug doxorubicin","volume":"278","author":"Sritharan","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2022.116912_b0165","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth","volume":"189","author":"Schlecker","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2022.116912_b0170","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.bmc.2022.116912_b0175","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2022.116912_b0180","doi-asserted-by":"crossref","first-page":"e60637","DOI":"10.7554\/eLife.60637","article-title":"PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response","volume":"9","author":"Kim","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.bmc.2022.116912_b0185","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2022.116912_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622003054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622003054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:18:23Z","timestamp":1760836703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622003054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"alternative-id":["S0968089622003054"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116912","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS\/STING immunity pathway combined with daunorubicin","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116912"}}